What question did this study set out to answer?

To assess whether breast cancer molecular subtypes affect the accuracy of magnetic resonance imaging (MRI) markers in monitoring tumor response during neoadjuvant chemotherapy.

January 11, 2011Journal of Clinical Oncology

Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype

View Full Paper

Ask AI

Bookmark

Authors

CLClaudette E. LooThe Netherlands Cancer Institute MSMarieke E. StraverMedisch Centrum Haaglanden SRSjoerd RodenhuisThe Netherlands Cancer Institute

Discussion

Member takes

Implication

Cohort study shows MRI response monitoring during neoadjuvant chemotherapy works in triple-negative and HER2-positive breast cancers, indicating limited accuracy for ER-positive disease.

Key Points

To assess whether breast cancer molecular subtypes affect the accuracy of magnetic resonance imaging (MRI) markers in monitoring tumor response during neoadjuvant chemotherapy.
Prospective evaluation of 188 women who underwent MRI before and during neoadjuvant chemotherapy.
Tumors were classified by immunohistochemistry into triple-negative (n=47), HER2-positive (n=38), and ER-positive/HER2-negative (n=103) subtypes.
MRI parameters (morphology, size, and contrast uptake kinetics) were analyzed against pathologic residual disease and the continuous breast response index using multivariate regression and ROC curves.
Pathologic residual tumor was detected in 66% (31/47) of triple-negative, 61% (23/38) of HER2-positive, and 93% (96/103) of ER-positive/HER2-negative tumors.
Multivariate analysis correlating residual disease with subtype and MRI demonstrated an AUC of 0.84 (P < .001), while breast response index correlated significantly with subtype, MRI, and age (Pearson r = 0.465, P < .001).
In triple-negative and HER2-positive cohorts, residual tumor significantly associated with changes in the largest diameter of late enhancement (AUC = 0.76, P < .001), but no significant MRI associations occurred in ER-positive/HER2-negative tumors.

Cite This Study

Loo et al. (2011) studied this question.

synapsesocial.com/papers/6a701df32163a0a01bc452db https://doi.org/10.1200/jco.2010.31.1258

View Full Paper

Ask AI

Bookmark

Implication

Cohort study shows MRI response monitoring during neoadjuvant chemotherapy works in triple-negative and HER2-positive breast cancers, indicating limited accuracy for ER-positive disease.

Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype

Discussion

Member takes

Implication

Key Points

Cite This Study

Magnetic Resonance Imaging Response Monitoring of Breast Cancer During Neoadjuvant Chemotherapy: Relevance of Breast Cancer Subtype

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider